5'ppp-dsRNA Control - RIG-I Agonist Negative Control

Negative control for 5′ppp-dsRNA

5’ppp-dsRNA Control is a negative control for 5’ triphosphate double-stranded RNA (5’ppp-dsRNA), a synthetic ligand for the retinoic acid-inducible protein I (RIG-I, also known as Ddx58). RIG-I is a cytoplasmic RNA helicase that belongs to the RIG-I-like receptors (RLRs) family and triggers an antiviral immune response by the activation of type-I interferons (IFN-α and -β) [1]. RIG-I detects viral RNAs that exhibit an uncapped 5’-di/triphosphate end and a short blunt-ended double-strand portion, two essential features facilitating discrimination from self-RNAs [2-4]. 5’ppp-dsRNA Control is a 19 mer blunt-end dsRNA without a 5’triphosphate.

5’ppp-dsRNA Control must be delivered into the cytoplasm, for example by using a transfection agent, such as LyoVec™.

Key features of 5'ppp-dsRNA Control:

• Negative control for the specific RIG-I specific agonist 5'ppp-dsRNA (it does not contain the 5' triphosphate moiety).
• Its biological activity has been verified using cellular assays.
• For your convenience, pre-complexed 5'ppp-dsRNA Control/ LyoVec™ is also available.

Read our review on RIG-I and cancer immunotherapy.

Learn more about RIG-I and STING alliance.

References:

1. Yoneyama M. & Fujita T., 2007.  Function of RIG-I-like Receptors in Antiviral Innate Immunity. J. Biol. Chem. 282:15315-8.
2. Schlee M. et al., 2009. Recognition of 5’ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in pandhandle of negative-strand virus. Immunity. 17;31(1):25-34.
3. Schmidt A. et al., 2009.  5’-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. PNAS 106(29):12067-72.
4. Schlee M. & Hartmann G., 2010. The chase for the RIG-I ligand - recent advances. Mol Ther. 18(7):1254-62.